Boehringer Ingelheim’ Investigational Combination Witnesses Positive Results

Boehringer Ingelheim has announced that the company has presented telmisartan and amlodipine combination data at the 19th Scientific Meeting of the European Society of Hypertension, Milan, Italy.

The data demonstrated that treatment with an investigational combination of telmisartan and amlodipine showed substantial and sustained 24-hour blood pressure (BP) lowering. Also, it is well-tolerated in a range of patients with hypertension at risk of cardiovascular (CV) events.

The study included patients with Type 2 diabetes, obese patients, and those not controlled by amlodipine alone.

The telmisartan and amlodipine combination was investigated in a double-blind trial involving 1461 patients with hypertension. These patients were randomised to one of 16 treatment arms involving telmisartan 0mg, 20mg, 40mg or 80mg plus amlodipine 0mg, 2.5mg, 5mg or 10mg for eight weeks.